19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Health Tip: Identifying Vascular DementiaOne Type of Dementia Is Especially CostlyA More Accurate Predictor for Alzheimer's?Failing Sense of Smell Tied to Dementia RiskMagnesium Levels Tied to Dementia RiskIs Dementia Declining Among Older Americans?Intracranial Pressure Monitoring No Benefit in Pediatric TBIGender-Specific High-Risk 'Window' Seen in Alzheimer'sWomen at Risk for Alzheimer's Face Critical 10-Year Window, Study SaysDo Fewer Nightly Dreams Mean Higher Dementia Risk in Seniors?Dementia Care: A Huge Financial Burden for U.S. FamiliesPopular Heartburn Drugs Don't Raise Risk of Alzheimer's: StudyFamilies Shoulder Majority of Costs Related to Dementia CareMidlife Vascular Risk Factors Tied to Increased Risk of DementiaBlood Pressure Fluctuations Tied to Dementia Risk in StudyMidlife Behaviors May Affect Your Dementia RiskTraveling With Dementia: Tips for Family CaregiversHigher Risk of Dementia Seen in Those Hailing From 'Stroke Belt'Health Tip: Alzheimer's Affects SleepIncreased Dementia Risk With Hearing Loss in Older AdultsNoninvasive Brain Test May Pinpoint Type of DementiaTargeting 9 Risk Factors Could Prevent 1 in 3 Dementia Cases: StudyAAIC: Rx + Training Shows Benefit in Advanced Alzheimer'sAAIC: Alzheimer Biomarkers Up With Sleep Disordered BreathingDozens of Potential Alzheimer's Meds in the PipelineSpecial Training Plus Medication Might Help People With Advanced Alzheimer'sOne Social Hour a Week Can Help Someone With DementiaSleep Problems: An Early Warning Sign of Alzheimer's?Severe Head Injury May Raise Dementia Risk Years LaterPPIs Not Found to Raise Risk of Alzheimer's DiseasePopular Heartburn Meds Don't Raise Alzheimer's Risk: StudyLifestyle Changes Might Prevent or Slow DementiaSevere Headaches Plague Vets With Traumatic Brain InjuriesSticky Brain 'Plaques' Implicated in Alzheimer's Again'Making the Best of It': Families Face the Heavy Burden of Alzheimer'sCognitive Decline Linked to Visual Field VariabilityAlzheimer's Deaths Jump 55 Percent: CDCLife Expectancy Slighter Shorter With Parkinson's, DementiaLow Body Mass Index Not Risk Factor for Alzheimer's DiseaseThin People Not More Prone to Alzheimer's, Study FindsWives, Daughters Shoulder Most of Alzheimer's Care BurdenGene Mutation May Speed Alzheimer's DeclineSilent Seizures May Contribute to Alzheimer's Pathology'Silent' Seizures Tied to Alzheimer's SymptomsPsychiatric Scars of Wartime Brain Injury May Linger for YearsMany Patients With Alzheimer's Disease Discontinue AChEIsMicrovascular Endothelial Dysfunction Can Predict DementiaAntipsychotic Medication Use Can Be Reduced in Dementia PatientsPast Psychiatric Disorders Do Not Raise Risk of Alzheimer's DiseasePast Psychiatric Ills Don't Raise Alzheimer's Risk: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Whether Statins Cut Alzheimer's Risk May Depend on Gender, Race

HealthDay News
by By Randy Dotinga
HealthDay Reporter
Updated: Dec 12th 2016

new article illustration

MONDAY, Dec. 12, 2016 (HealthDay News) -- Could cholesterol-fighting statins fend off Alzheimer's disease?

A new, large study suggests that if they do have that power, it may depend on the specific statin, and the gender and race or ethnicity of the person taking it.

For example, black men appeared to gain no benefit from taking any statin, while white women may lower their risk regardless of which statin they take, the researchers said.

The findings don't prove that statins reduce the chances of developing Alzheimer's. And if they do shrink the risk, the effect seems to be small.

Still, "those with high exposure to statins had a reduced risk of [Alzheimer's disease] compared to those with low exposure. And it varied by type of statin and for men, women and for different racial and ethnic individuals," said study author Julie Zissimopoulos. She is associate director of the Schaeffer Center for Health Policy and Economics at the University of Southern California in Los Angeles.

Previous research has suggested that high cholesterol in later life seems to boost the risk of Alzheimer's disease while statins reduce it, said Dr. Gail Li. She is an associate professor in the department of psychiatry and behavioral sciences at the University of Washington in Seattle.

But Li, who was not involved with the new study, added that statins don't seem to help patients who already have Alzheimer's.

The new study aimed to understand how specific groups of people might be affected by the therapy.

The researchers tracked almost 400,000 statin users, all aged 65 or older, who took the medications between 2006 and 2013.

In the study, Zissimopoulos said, "We examine individuals who have been taking statins consistently for at least two years, between the years 2006 and 2008, and follow them for another five years to examine onset of Alzheimer's. We compare them to groups of individuals with low exposure that either took statins less consistently between 2006 and 2008, or started them later -- after 2008."

Overall, the researchers linked high use of statins to a 15 percent lower risk of Alzheimer's in women and a 12 percent lower risk in men compared to those who had low use.

Those who took simvastatin (Zocor) had 10 percent to 23 percent lower risk, depending on their gender and race. However, the researchers saw no benefit for black men.

Among those who used atorvastatin (Lipitor) the most, white men and black men had no apparent benefit, while the risk of Alzheimer's was 16 percent to 39 percent lower for white women, black women and Hispanics.

Only white women appeared to gain a benefit from high usage of pravastatin (Pravachol) and rosuvastatin (Crestor): They had about an 18 percent lower risk of developing Alzheimer's disease, the findings showed.

According to Zissimopoulos, the lifetime risk of developing Alzheimer's disease is between 9 percent and 17 percent at the age of 65.

For her part, Li is skeptical of the new findings. She eyed the results with caution, saying there may be too few people in some of the ethnic groups to come up with statistically reliable conclusions.

Dr. Benjamin Wolozin, a professor with the departments of pharmacology and neurology at Boston University School of Medicine, said genetics may explain the differences between the groups. As to why statins may reduce Alzheimer's risk, he said it may have something to do with the power of the drugs to promote good blood flow to the brain.

An expert in aging research, Dr. Eric Larson, executive director of the Group Health Research Institute in Seattle, had another theory: "Some of the variation could be based on patterns of care -- how drugs are prescribed to different types of patients and also the baseline levels of vascular risk. Black men are likely to have more than just high cholesterol levels -- [they may have] other conditions that increase risk and aren't affected by statins."

What should people who use statins do?

Larson said, "People who have high levels of cholesterol and other conditions that predispose them to vascular diseases should definitely consider taking statins for their benefit in general, and can also feel like they are doing something for their risk of dementia and Alzheimer's."

But, he added, "I would not use the results of this study to guide choices of statins. Things like tolerability, cost and so forth may be more important for many people."

The study was published online Dec. 12 in the journal JAMA Neurology.

More information

For more about statins and Alzheimer's, visit Cognitive Vitality, part of the Alzheimer's Drug Discovery Foundation.